So, PETX received $5.4-$2.2 or $3.2 million of actual product revenue from Galliprant in Q3 2017, so on March 14th, we will have another data point on Galli’s organic growth rate. It should at least double, I hope..................
Hope has even fled the White House again. I don't put much store by that purported virtue but I would be very disappointed by a decline in retail sales which are not directly related to inventory sales.
In our case we had a devil of a time getting any Galliprant tablets because we first needed a prescription from a vet who knew nothing at all about the drug for our 7-year-old mixed border collie and then we quickly found we couldn't buy the drug anywhere in our area.
Happens when you live in the sticks.
There was a break because of another snafu after the first month's supply was used and the dog quickly became a cripple again.
Long term questions remain to be answered in the - ahem - long term and that is even now of great interest to our vet with his "animal hospital."
Galliprant as a first-in-class piprant does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions.
It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation1